Valeant Pharmaceuticals Completes Sale of Certain European Operations to Meda AB

16-Sep-2008 - USA

Valeant Pharmaceuticals International announced that it has completed its sale of certain business operations located in Western Europe, Eastern Europe, and certain export markets to Meda AB, pursuant to the Acquisition Agreement entered into by Meda and Valeant on August 4, 2008. Valeant received approximately US$425 million in cash from Meda at closing, which is subject to certain closing adjustments.

Goldman, Sachs & Co. served as financial advisor to Valeant and Skadden, Arps, Slate, Meagher & Flom LLP provided legal advice.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances